Icahn School of Medicine at Mount Sinai Listed a New Clinical Trial of Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Press/Media

Period10 Oct 2019

Media coverage

1

Media coverage

  • TitleIcahn School of Medicine at Mount Sinai Listed a New Clinical Trial of Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date10/10/19
    PersonsThomas Marron
View all 1
View less